AVCN.TO Stock - Avicanna Inc.
Unlock GoAI Insights for AVCN.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $25.46M | $16.79M | $4.05M | $3.27M | $1.57M |
| Gross Profit | $12.90M | $6.66M | $1.11M | $2.83M | $-570,000 |
| Gross Margin | 50.7% | 39.7% | 27.5% | 86.6% | -36.3% |
| Operating Income | $-4,680,000 | $-7,933,000 | $-10,410,000 | $-11,413,000 | $-18,988,000 |
| Net Income | $-3,618,000 | $-8,743,000 | $-14,735,000 | $-16,775,000 | $-32,862,000 |
| Net Margin | -14.2% | -52.1% | -364.0% | -513.2% | -2093.1% |
| EPS | $-0.04 | $-0.10 | $-0.25 | $-0.41 | $-1.12 |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
AVCN.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 14, 2025 | — | $0.00 | — | — |
Q2 2025 | Apr 11, 2025 | — | $0.00 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.01 | — | — |
Q2 2024 | Apr 1, 2024 | — | $-0.03 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.02 | — | — |
Q1 2023 | Mar 31, 2023 | $-0.03 | $-0.03 | -10.3% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $-0.06 | $-0.18 | -200.0% | ✗ MISS |
Q4 2022 | Nov 11, 2022 | $-0.03 | $-0.05 | -61.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.04 | $-0.08 | -100.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.05 | $-0.02 | +59.2% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.06 | $-0.18 | -200.0% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.06 | — | — |
Q3 2021 | Sep 7, 2021 | $-0.04 | $-0.14 | -250.0% | ✗ MISS |
Q3 2021 | Sep 4, 2021 | $-0.08 | $-0.18 | -125.0% | ✗ MISS |
Latest News
Frequently Asked Questions about AVCN.TO
What is AVCN.TO's current stock price?
What is the analyst price target for AVCN.TO?
What sector is Avicanna Inc. in?
What is AVCN.TO's market cap?
Does AVCN.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AVCN.TO for comparison